For Clinicians and Researchers
This page exists because the frameworks on this site use new terminology — and clinicians and researchers encountering them for the first time deserve a clean translation to established constructs.
The frameworks on this page were developed through direct observation across intake and program settings over more than two decades — not through formal clinical research. The observations are consistent with established pharmacological mechanisms and are offered as pattern-recognition tools, not validated clinical instruments.
The terminology is new. The mechanisms are not.
What Pivot Protocols has named — CCOD, GBAD, HFO, Activation Slope Induction, the Pharmacologic Cycle Overwrite — are pattern-recognition and sequencing frameworks built from repeated observations across this population and interpreted through established pharmacology. They are not diagnostic classifications. They are not clinical guidelines. They are organizational tools for a population and a presentation that existing frameworks hadn't yet formally addressed.
If there were existing language that captured these patterns cleanly, we would use it. The new terms exist because the patterns they describe didn't have names — not because the mechanisms behind them are unfamiliar.
What Pivot is — and is not
Pivot Protocols is a behavioral consulting practice. It does not prescribe medication, provide therapy, or constitute a clinical service. All clinical decisions remain between the client and their licensed medical provider.
What Pivot provides is a sequencing and stabilization architecture — pattern assessment, VDI-guided stability monitoring, behavioral containment, and structured exit support. The clinical layer belongs with the prescriber. Pivot manages the behavioral and sequencing layer alongside it.
Framework translation table
The following maps each Pivot term to its closest established clinical equivalent. These are not identical — the Pivot terms organize specific observations that the standard language doesn't fully capture — but the mapping shows where the frameworks are grounded.
High Frequency Opioids (HFO)
Pivot definition: A compound class defined by high mu-opioid receptor potency combined with short duration of action — producing repeated interdose withdrawal events when used as directed.
Clinical utility note: HFO is a clinical utility term, not a pharmacological classification. It names a pattern observation: that short-acting, high-potency partial agonists in retail consumer form produce a distinct dependence picture driven by dosing frequency rather than potency alone.
Established language equivalent: Short-acting, high-reinforcement-cycle opioid exposure.
Grounding: Mu-opioid receptor pharmacodynamics; partial agonist dose-response curves; interdose withdrawal mechanics in short half-life compounds.
Compressed-Cycle Opioid Dependence (CCOD)
Pivot definition: A distinct dependence pattern produced by HFO use — characterized by interval compression, multiple daily withdrawal events, progressive nervous system destabilization, and a clinical presentation pharmacologically and behaviorally distinct from classical full agonist dependence in tempo rather than kind.
Established language equivalent: Interval compression with repeated interdose withdrawal; opioid use disorder with short-cycle reinforcement pattern.
Grounding: Reinforcement learning and cue-salience literature; interdose withdrawal mechanics; Robinson and Berridge incentive sensitization framework; pattern observation across this population.
Note: CCOD is not a DSM diagnostic category. It is a pattern-recognition framework identifying a clinical subpopulation within the broader opioid use disorder spectrum whose presentation warrants distinct sequencing approaches.
G-protein Biased Autonomic Dysregulation (GBAD)
Pivot definition: The withdrawal presentation produced by kratom alkaloid and 7-OH use — simultaneously autonomic and emotional, time-locked to the dosing schedule, and not captured by standard clinical assessment instruments including COWS.
Established language equivalent: Time-locked affective and autonomic withdrawal; overlapping noradrenergic activation and mu-opioid emotional regulatory disruption; interdose affective instability in short-acting partial agonist use.
Grounding: G-protein biased agonism at the mu-opioid receptor (Kruegel et al., Nature Communications, 2021); mu-opioid system regulation of affective responses (Zubieta JK et al., Arch Gen Psychiatry, 2003); mu-opioid system and social pain/grief processing (Hsu DT et al., Molecular Psychiatry, 2013); endogenous opioid emotion regulation (Kennedy SE et al., Arch Gen Psychiatry, 2006).
Note: The emotional dimension of GBAD — affective cycling tied to the pharmacokinetic schedule — is not captured by COWS, which was designed and validated for full agonist opioid withdrawal with a 12–24 hour arc. The CCOD population's relevant window closes in 2–3 hours. This gap has direct implications for induction timing and patient assessment.
Activation Slope Induction
Pivot definition: A timing framework for buprenorphine induction in the HFO/CCOD population — identifying the correct induction window based on where the patient sits on the descending activation curve rather than time since last dose.
Established language equivalent: Partial agonist induction timing in short half-life opioid dependence; modified induction protocol for interdose withdrawal population.
Grounding: Buprenorphine partial agonist pharmacodynamics; precipitated withdrawal mechanics in partial-to-partial transitions; pattern observation that standard COWS-based induction timing fails this population because the scoring threshold is not reached within the available window.
Note: Standard induction protocols apply a timing signal calibrated for full agonist dependence. In the CCOD population the relevant signal is position on the descending activation curve — not hours since last dose. Applying the wrong timing signal results in failed induction before treatment has begun.
Pharmacologic Cycle Overwrite (PCO)
Pivot definition: A short-term buprenorphine detoxification approach applied to the CCOD population — addressing both the pharmacological sawtooth cycle and the neurophysiological reorganization produced by high-frequency activation within a defined clinical window, using the medication's own 37-hour half-life to complete a passive linear exit.
Established language equivalent: Frequency reduction via long-acting partial agonist stabilization; short-term buprenorphine detoxification in short-cycle partial agonist dependence.
Grounding: Original buprenorphine short-term detox clinical application (Wesson DR, Ling W, Journal of Psychoactive Drugs, 2003); kratom to buprenorphine transition without precipitated withdrawal (Broyan, Brar, Allgaier et al., Substance Abuse, 2022 — 28 patients, zero precipitated withdrawal); 7-OH potency data (Takayama et al. 2002; Hemby SE et al., Addiction Biology, 2019).
Note: PCO is not a new treatment. It is the original short-term detox use case for buprenorphine applied to a dependence pattern that didn't exist when those protocols were written. It is not maintenance. It is a defined clinical window with a defined exit.
Volatility Density Index (VDI)
Pivot definition: A proprietary scoring instrument measuring nervous system instability across five domains — sleep continuity, dosing intervals, urge pressure, redosing behavior, and emotional regulation — producing a directional signal about system readiness for dose reduction.
Established language equivalent: Multivariate withdrawal instability assessment; stability-gated taper sequencing instrument.
Grounding: Sleep continuity as primary stability marker in opioid withdrawal literature; interval compression as dependence severity indicator; withdrawal symptom clustering in taper failure research.
Note: The VDI does not measure dose. It measures the conditions that determine whether a reduction will hold. Stability precedes reduction — and stability is assessed instrumentally rather than assumed.
Pattern Trajectory
Pivot definition: The directional arc of instability over time — stabilizing, static, or deteriorating. Pattern Trajectory transforms a VDI score from a snapshot into a vector, indicating not just where the system is but where it is heading.
Established language equivalent: Longitudinal instability trending; withdrawal trajectory assessment.
Note: A patient with a moderate VDI score whose pattern is stabilizing is in a fundamentally different clinical position than a patient with the same score whose pattern is tightening. The direction matters as much as the number.
A clinical note on COWS
COWS was designed and validated for full agonist opioid withdrawal — a withdrawal arc that takes 12 to 24 hours to develop. It isn't wrong. It's calibrated for a different patient.
When applied to the CCOD population it encounters two specific gaps. First, the timing gap — the induction window closes in 2 to 3 hours, before the COWS-weighted symptoms have fully developed. A patient who doesn't score ≥8 or ≥12 on COWS within that window is not insufficiently withdrawn. They are in a different withdrawal arc. Second, the emotional gap — the affective cycling that constitutes the GBAD presentation doesn't appear on COWS at all.
The COWS and the Kratom Population page documents this in full.
Longitudinal context: The Persistent Pathway
The Persistent Pathway describes what high-frequency partial agonist activation does to the reward system architecture over sustained exposure — and what remains after the cycle stops. D2 receptor downregulation, ΔFosB accumulation, and allostatic baseline shift don't resolve on acute detox timelines. The post-exit window is neurologically distinct from standard early recovery — flatter, longer, and more vulnerable to cross-sensitization from new activating signals.
For providers seeing patients who have exited a CCOD pattern but are struggling in the post-exit window with anhedonia, emotional dysregulation, or unexpectedly rapid relapse acceleration — the Persistent Pathway framework explains why the post-exit window requires active attention rather than a return to standard aftercare protocols.
What this population looks like in practice
This population may be presenting in your practice already — or it may not be yet. Either way, the clinical picture is worth knowing.
Patients using kratom extracts or 7-OH products may present with anxiety, emotional dysregulation, and apparent depression whose symptoms track the dosing schedule rather than presenting as stable mood disorder. That pattern is the GBAD picture — pharmacokinetically produced and potentially misread as comorbid psychiatric illness if the dosing schedule isn't part of the intake assessment.
Buprenorphine induction attempts may fail in ways that don't match the standard precipitated withdrawal picture — because the relevant window closes in 2 to 3 hours and the COWS threshold may not be reached within it. Taper attempts may collapse at predictable thresholds despite patient motivation because sequencing was attempted inside instability rather than from a stabilized baseline.
This population is growing, the compounds are increasingly accessible, and the clinical picture is distinct enough that standard approaches will fail it in predictable ways.
Referral pathway
Pivot Protocols works alongside prescribing providers — not around them. Pivot manages the non-clinical side: stability assessment using the VDI, behavioral containment, sequencing guidance, and structured exit support. All clinical decisions remain with the prescriber.
The Quit Plan Builder provides a rapid pattern assessment — six questions, no login required — that can serve as a useful intake signal.
For direct conversation about a specific patient or referral text me here:
651-270-2358
Citation reference
Takayama H et al. J Med Chem. 2002;45(9):1949–56.
Hemby SE et al. Addiction Biology. 2019;24(5):874–885.
Kruegel AC et al. Nature Communications. 2021.
Zubieta JK et al. Arch Gen Psychiatry. 2003;60:1145–53.
Kennedy SE et al. Arch Gen Psychiatry. 2006;63:1199–208.
Hsu DT et al. Molecular Psychiatry. 2013;18:1211–17.
Pecina M et al. JAMA Psychiatry. 2015;72:1087–94.
Broyan A, Brar J, Allgaier H et al. Substance Abuse. 2022.
Wesson DR, Ling W. Journal of Psychoactive Drugs. 2003.
SAMHSA TIP 63. Medications for Opioid Use Disorder.
Pivot Protocols is a behavioral consulting practice and does not provide medical, clinical, or mental health services. All clinical decisions are made solely between the patient and their licensed medical provider. The frameworks on this site are offered for educational and pattern-recognition purposes and do not constitute diagnostic classifications or clinical guidelines.
John Leonard is the founder of Pivot Protocols and a recovery program leader with 23 years of front-line experience. The frameworks on this site were developed through direct observation, pattern recognition, and grounding in published pharmacological research. He is not a clinician or medical provider.